Results 271 to 280 of about 167,880 (309)
Some of the next articles are maybe not open access.
Scandinavian Journal of Haematology, 1969
A clinical series of 40 patients was observed for 5 months, in the course of which every patient took 1.5 g. metformin daily for 3 months. No increase in fibrinolytic activity was demonstrable by euglobulin lysis test during the course of treatment. Nor did the fibrinogen and cholesterol values change. Blood glucose decreased.
openaire +2 more sources
A clinical series of 40 patients was observed for 5 months, in the course of which every patient took 1.5 g. metformin daily for 3 months. No increase in fibrinolytic activity was demonstrable by euglobulin lysis test during the course of treatment. Nor did the fibrinogen and cholesterol values change. Blood glucose decreased.
openaire +2 more sources
Drugs, 2005
The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output. Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control.
openaire +2 more sources
The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output. Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control.
openaire +2 more sources
Rejuvenation Research, 2011
Geroprotectors are drugs that decrease the rate of aging and therefore extend life span. Metformin has been described as a geroprotector, and several studies have shown that metformin can slow down the rate of aging. The mechanisms behind the geroprotective effect of metformin are less established. The goal of this review is to investigate the evidence
openaire +2 more sources
Geroprotectors are drugs that decrease the rate of aging and therefore extend life span. Metformin has been described as a geroprotector, and several studies have shown that metformin can slow down the rate of aging. The mechanisms behind the geroprotective effect of metformin are less established. The goal of this review is to investigate the evidence
openaire +2 more sources
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2016
Metformin is the first choice among drugs used for the treatment of type II diabetes mellitus mainly because of several advantages: proven hypoglycemic effect, good safety profile, virtually no risk of hypoglycemia, body weight reduction, lipid-lowering effect, efficacy in preventing micro- and macrovascular complications as well as adverse cardiac and
Sessa C +5 more
openaire +2 more sources
Metformin is the first choice among drugs used for the treatment of type II diabetes mellitus mainly because of several advantages: proven hypoglycemic effect, good safety profile, virtually no risk of hypoglycemia, body weight reduction, lipid-lowering effect, efficacy in preventing micro- and macrovascular complications as well as adverse cardiac and
Sessa C +5 more
openaire +2 more sources
Cellular and Molecular Mechanisms of Metformin Action
Endocrine Reviews, 2021Traci E Lamoia, Gerald I. Shulman
exaly
Benefits of Metformin in Attenuating the Hallmarks of Aging
Cell Metabolism, 2020Nir Barzilai +2 more
exaly